GLPG2222 300 mg q.d. ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis1

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03045523
(ClinicalTrials.gov)
January 201726/1/2017A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic FibrosisA Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) MutationCystic FibrosisDrug: GLPG2222 150 mg q.d.;Drug: GLPG2222 300 mg q.d.;Drug: PlaceboGalapagos NVNULLCompleted18 Years99 YearsAll37Phase 2Australia;Belgium;Czechia;Germany;Ireland;United Kingdom